Anavex Life Sciences Corp. (AVXL.OB) Announces $10 Million Private Placement Of Convertible Debentures
3/13/2014 8:49:28 AM
NEW YORK, March 13, 2014 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (OTCQB:AVXL), a clinical stage biopharmaceutical company developing novel drug candidates to treat Alzheimer's, diseases of the central nervous system (CNS) and various types of cancer, announced today that it has entered into definitive agreements with several institutional and accredited investors, including U.S. and international healthcare funds, for a private placement of approximately $10 million in principal amount of convertible debentures. In addition, the investors will receive warrants to purchase up to approximately 66.7 million shares of common stock in the aggregate.
Help employers find you! Check out all the jobs and post your resume.
comments powered by